Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Aradigm Corporation (NasdaqNM:ARDM)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 24Price hit new 52-week low ($4.10)
Location
3929 Point Eden Way
Hayward, CA 94545
Phone: (510) 265-9000
Fax: (510) 265-0277
Email: investor@aradigm.com
Employees (last reported count): 256
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 20%
·Over the last 6 months:
 · 4 insider sells; 206.0K shares
  (4.9% of insider shares)
·Institutional: 50% (63% of float)
(105 institutions)
·Net Inst. Buying: 3,000  shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Aradigm Corporation is a developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. The Company's hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung. The Company's non-invasive AERx systems have been shown in clinical studies to achieve performance equivalent to injection-based delivery systems. In addition, the Company's systems may improve therapeutic efficacy in cases where other existing drug delivery methods, such as pills, transdermal patches or inhalers, are too slow or imprecise.
More from Market Guide: Expanded Business Description

Financial Summary
Aradigm is engaged in the development of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. For the six months ended 6/30/01, revenues rose 45% to $15.2 million. Net loss before extraordinary item rose 18% to $18.6 million. Results reflect revenues derived from collaboration agreements with Novo Nordisk A/S and GlaxoSmithKline, offset by increased R and D expenses related to the development of the AERx System.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Richard Thompson, 49
Chairman, Pres, CEO
$407K
Michael Molkentin
Acting CFO, Controller
--  
R. Jerald Beers, 52
Exec. VP, Marketing and Bus. Devel.
256K
Norma Milligin, 62
VP, HR
--  
Bikash Chatterjee, 42
VP, Pharmaceutical Operations
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ARDMAs of 31-Aug-2001
Price and Volume
52-Week Low
on 24-Aug-2001
$4.10 
Recent Price$4.30 
52-Week High
on 3-Nov-2000
$27.438
Beta1.26 
Daily Volume (3-month avg)134.7K
Daily Volume (10-day avg)124.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-75.4%
52-Week Change
relative to S&P500
-67.0%
Share-Related Items
Market Capitalization$86.1M
Shares Outstanding20.0M
Float16.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.11 
Earnings (ttm)-$2.07 
Earnings (mrq)-$0.47 
Sales (ttm)$1.35 
Cash (mrq)$1.05 
Valuation Ratios
Price/Book (mrq)2.04 
Price/EarningsN/A 
Price/Sales (ttm)3.19 
Income Statements
Sales (ttm)$25.0M
EBITDA (ttm)-$35.5M
Income available to common (ttm)-$38.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-52.34%
Return on Equity (ttm)-85.66%
Financial Strength
Current Ratio (mrq)1.02 
Debt/Equity (mrq)0.20 
Total Cash (mrq)$20.8M
Short Interest
As of 8-Aug-2001
Shares Short495.0K
Percent of Float3.1%
Shares Short
(Prior Month)
423.0K
Short Ratio3.54 
Daily Volume140.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.